Systemic physostigmine increases the antinociceptive effect of spinal morphine

Area of Science:

• Neuroscience
• Pharmacology
• Pain Management

Background:

• Opioid analgesics like morphine are commonly used for pain relief.
• Physostigmine, an acetylcholinesterase inhibitor, has shown potential in modulating pain pathways.
• Understanding drug interactions is crucial for optimizing pain management strategies.

Purpose of the Study:

• To evaluate the antinociceptive effects of combined intrathecal morphine and subcutaneous physostigmine.
• To analyze the interaction between these two drugs using a dose-addition model.
• To investigate potential supra-additive effects in pain modulation.

Main Methods:

• Experiments were conducted on male Wistar rats using a tail-immersion test.
• Morphine was administered intrathecally (i.t.) and physostigmine subcutaneously (s.c.).
• Drug interactions were assessed by comparing observed effects to predicted additive effects.

Main Results:

• Both i.t. morphine and s.c. physostigmine demonstrated dose-dependent antinociceptive effects.
• A combination of low doses (1 microg i.t. morphine and 50 microg/kg s.c. physostigmine) produced a significant antinociceptive effect (%MPE = 84.8 +/- 16.9).
• The observed effect was significantly greater than the sum of individual drug effects, indicating supra-additivity.

Conclusions:

• Concurrent administration of i.t. morphine and s.c. physostigmine yields a strong antinociceptive effect.
• The supra-additive interaction suggests synergistic mechanisms in pain processing at central nervous system levels.
• This combination therapy holds promise for enhanced pain management, potentially reducing required doses and side effects.